ORI can potentiate the anticancerous potential of gemcitabine drug in pancreatic cancer by activation of p53 that mediates MAPK‐p38 signaling pathway (Bu et al., 2012). This evidence concerns the gene TP53 and familial pancreatic carcinoma.